價(jià)格 | 詢(xún)價(jià) | ¥4820 | ¥1930 |
包裝 | 50mg | 5mg | 1mg |
最小起訂量 | 1mg |
發(fā)貨地 | 上海 |
更新日期 | 2024-12-12 |
中文名稱(chēng):3-脫氧葡萄糖醛酮 | 英文名稱(chēng):3-Deoxyglucosone |
CAS:4084-27-9 | 品牌: TargetMol |
產(chǎn)地: 美國(guó) | 保存條件: store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
純度規(guī)格: 95% | 產(chǎn)品類(lèi)別: 抑制劑 |
貨號(hào): T19117 |
Name | 3-Deoxyglucosone |
Description | 3-Deoxyglucosone(3-Deoxy-D-glucosone) is synthesized by the intermediate pathway of the melad and polyol reactions.3-Deoxyglucosone reacts rapidly with protein amino groups to form advanced glycosylated end proteins (AGEs).3-Deoxyglucosone inactivates glutathione peroxidase and synergizes with low glucose to enhance GLP-1 secretion.3-Deoxyglucosone is used as a biomarker for diabetes mellitus.3-Deoxyglucosone has been shown to be an inhibitor of GLP-1 secretion in the presence of low glucose. 3-Deoxyglucosone inactivates glutathione oxidase, synergizes with low glucose to enhance GLP-1 secretion, and can be used as a biologic marker for diabetes. |
Cell Research | Cell Line: STC-1 cells. Concentration: 300?ng/ml. Incubation Time: 1 hour [1] |
Animal Research | Animal Model: SD rats. Dosage: 5, 20 and 50 mg/kg. Administration: oral administration; once daily; 2 weeks [3] |
In vitro | 3-Deoxyglucosone(80 ng/ml-1000 ng/ml;1小時(shí);STC-1細(xì)胞)在300 ng/ml及1000 ng/ml的處理組中顯著誘導(dǎo)GLP-1分泌增加1.23倍。然而,在80 ng/ml的較低濃度下,未觀(guān)察到明顯效應(yīng)。值得注意的是,3-Deoxyglucosone在300 ng/ml的濃度顯著提高了細(xì)胞內(nèi)Ca2+水平,通過(guò)Fluo-3/AM(2.5 μM,30分鐘)確定。相比之下,3DG不影響cAMP Elisa試驗(yàn)中的細(xì)胞內(nèi)cAMP水平。此外,在300 ng/ml的濃度下,3-Deoxyglucosone顯著增強(qiáng)了TAS1R2、TAS1R3和TRPM5的蛋白表達(dá)水平,無(wú)論是在無(wú)葡萄糖還是高葡萄糖條件下。 |
In vivo | 3-Deoxyglucosone (20 mg/kg;經(jīng)口投給;單劑量)會(huì)導(dǎo)致葡萄糖耐量變差,這一變化通過(guò)Area Under the Curve (AUC)的增加得到證實(shí)。血漿胰高血糖素水平?jīng)]有顯示出顯著差異。3-Deoxyglucosone的投給導(dǎo)致了顯著的糖調(diào)節(jié)受損(IGR),伴隨著昆明鼠和SD大鼠胰島細(xì)胞功能明顯的失調(diào)。[2] 3-deoxyglucosone (5-50 mg/kg;經(jīng)胃管灌注;每天一次;2周;SD大鼠)在上小腸(1.4倍)、下小腸(1.4倍)、回腸(1.4倍)和結(jié)腸(兩倍)部位展示了與各自對(duì)照組基礎(chǔ)水平相比的顯著增加。此外,觀(guān)察到十二指腸和結(jié)腸中TAS1R2、TAS1R3和TRPM5的蛋白表達(dá)顯著減少。[3] |
Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Keywords | 3-Deoxyglucosone |
Inhibitors Related | 6α-Methylprednisolone 21-hemisuccinate sodium salt | PF-06882961 | LSN3318839 | RSL3 | N6F11 | Orforglipron | NNC 92-1687 | ML162 | (S, R)-LSN 3318839 | Tirzepatide Acetate(2023788-19-2 free base) |
成立日期 | 2013-04-18 (12年) | 注冊(cè)資本 | 566.265100萬(wàn)人民幣 |
員工人數(shù) | 100-500人 | 年?duì)I業(yè)額 | ¥ 1億以上 |
主營(yíng)行業(yè) | 天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù) | 經(jīng)營(yíng)模式 | 貿(mào)易,工廠(chǎng),試劑,定制,服務(wù) |
產(chǎn)品名稱(chēng) | 價(jià)格 | 公司名稱(chēng) | 報(bào)價(jià)日期 | |
---|---|---|---|---|
¥15000 |
VIP9年
|
湖北威德利化學(xué)試劑有限公司
|
2024-12-27 | |
詢(xún)價(jià) |
VIP5年
|
武漢華玖醫(yī)藥科技有限公司
|
2024-12-27 | |
詢(xún)價(jià) |
VIP3年
|
湖北健楚生物醫(yī)藥有限公司
|
2024-12-27 | |
詢(xún)價(jià) |
VIP3年
|
河南威梯希化工科技有限公司
|
2024-12-27 |